On the stock market since 2024, it operates in the world of health and science. It has 51 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
There is $262.9M in the vault; even if every debt were paid off, $254.6M would remain.
A loss of $60.0M against $0 in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 47/100.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, CTNM sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CTNM is a high-risk stock — not yet profitable, and its future rides on its product catching on.